Related Experiment Videos
Improved carrier testing for multiple endocrine neoplasia, type 1, using new microsatellite-type DNA markers
S Kytölä1, J Leisti, R Winqvist
1Department of Medical Genetics, Oulu University Central Hospital, Finland.
Human Genetics
|October 1, 1995
Summary
Genetic analysis of familial multiple endocrine neoplasia, type 1 (FMEN1) families identified specific DNA markers on chromosome 11q13. These markers significantly enhance the diagnostic accuracy for individuals at risk of developing FMEN1.
Area of Science:
- Genetics
- Endocrinology
- Molecular Biology
Background:
- Familial multiple endocrine neoplasia, type 1 (FMEN1) is an autosomal dominant disorder characterized by the hyperfunction of multiple endocrine glands.
- The gene responsible for FMEN1 has been localized to chromosome 11q13.
Purpose of the Study:
- To refine the genetic linkage map of the FMEN1 gene on chromosome 11q13.
- To evaluate the diagnostic utility of specific microsatellite DNA markers for FMEN1 risk assessment.
Main Methods:
- Genotyping of eight Finnish families (46 individuals) using four polymorphic microsatellite DNA markers (D11S913, D11S987, D11S1337, D11S971) spanning the MEN1 chromosomal region.
- Analysis of genetic linkage and recombination fractions to determine the proximity of markers to the FMEN1 disease gene.
Main Results:
- Three markers (D11S913, D11S987, D11S1337) showed maximum lod scores (Zmax) of 6.70, 9.88, and 2.54, respectively, with no observed recombinations.
- Marker D11S971 yielded a Zmax of 8.43 at a recombination fraction of 0.03, indicating close linkage to the FMEN1 gene.
- The combined use of these markers demonstrated high diagnostic value.
Conclusions:
- The selected microsatellite markers provide a valuable tool for genetic linkage analysis in FMEN1.
- Improved genotyping accuracy facilitates early diagnosis and risk assessment for familial multiple endocrine neoplasia, type 1.